CVE-2015-5317
Published: May 12, 2023
Official Description
Jenkins User Interface (UI) contains an information disclosure vulnerability that allows users to see the names of jobs and builds otherwise inaccessible to them on the "Fingerprints" pages.
CISA KEV Advisory
Jenkins User Interface (UI) Information Disclosure Vulnerability
Jenkins User Interface (UI) contains an information disclosure vulnerability that allows users to see the names of jobs and builds otherwise inaccessible to them on the "Fingerprints" pages.
Apply updates per vendor instructions.
Risk Analysis
This information disclosure vulnerability in Jenkins User Interface (UI) allows unauthorized users to view job and build names that should otherwise be inaccessible. The high EPSS score and its inclusion in CISA's KEV catalog indicate that this vulnerability is actively exploited and has a high probability of being targeted.
This vulnerability has been actively exploited in the wild. The exploitation involves accessing specific "Fingerprints" pages within the Jenkins UI.
Administrators should ensure Jenkins instances are updated to patched versions. Review and enforce strict access controls for Jenkins UI to limit information exposure.
Technical Analysis
CVE-2015-5317 requires local access, meaning attackers must already have a foothold on the target system.
Exploitation requires some privileges, which limits the exposure to scenarios where an attacker has already gained initial access.
CISA has added CVE-2015-5317 to the Known Exploited Vulnerabilities (KEV) catalog, confirming active exploitation in the wild. U.S. federal agencies are required to patch this within the mandated timeframe, and all organizations should treat remediation as urgent.
Exploit & PoC Resources
All References (2)
Quick Facts
Recommended Actions
- →Apply vendor patches immediately
- →Monitor CVE-2015-5317 in threat intel feeds
- →Review IDS/IPS signatures for exploitation attempts
- !CISA KEV: Federal agencies must patch per BOD 22-01 timeline
- !Active exploitation confirmed — treat as P1